Videos

The professor and chair of neurology at Virginia Commonwealth University discussed how neurologists are urged to take organized action and provide training on healthcare disparities, with a particular focus on race, ethnicity, and financial barriers to access. [WATCH TIME: 2 minutes]

Neurology News Network for the week ending January 6, 2023. [WATCH TIME: 3 minutes]

The director of the Ann Kimball and John W. Johnson Center for Cellular Therapeutics at Houston Methodist Hospital discussed the clinical manifestations of frontotemporal dementia (FTD) and how Coya Therapeutics is moving toward precision medicine with their FTD candidate, COYA 301. [WATCH TIME: 4 minutes]

The professor of neurology at Cedars-Sinai Medical Center talked about efgartigimod as a novel treatment for chronic inflammatory demyelinating polyneuropathy, with the potential of it being a first-line treatment for patients with the condition. [WATCH TIME: 3 minutes]

The director of neurocritical care and emergency neurology services at Westchester Medical Center Health System talked about a recently published paper that highlighted the need to address the disparity in quality metrics for stroke care, especially for intracerebral hemorrhage. [WATCH TIME: 4 minutes]

The vice president of the Rare Disease Translational Center at the Jackson Laboratory provided commentary on the next steps needed to further understand stathmin-2’s role as a potential disease-modifying biomarker. [WATCH TIME: 3 minutes]

The expert neurologists discuss non-motor symptoms of Parkinson’s disease: types, their impact on patient’s quality of life, and current and emerging treatment options for non-motor symptoms.

The chief scientific officer at Athira Pharma talked about preclinical results presented at the 2023 Society for Neuroscience Annual Meeting on fosgonimeton, a potential treatment for Alzheimer disease and other neurodegenerative diseases. [WATCH TIME: 6 minutes]

The chief medical research officer and head of research at Aviv Clinics discussed the impact of long COVID on patients and shared findings from a recently published study on using hyperbaric oxygen therapy protocol as a treatment for these patients. [WATCH TIME: 8 minutes]

The medical director of the Inpatient Rehabilitation Unit at Ascension Genesys Hospital provided her clinical perspective on what comprehensive care looks like for the millions of patients who experience stroke and are recovering. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending December 23, 2023. [WATCH TIME: 4 minutes]

The chief medical officer of Acadia Pharmaceuticals provided commentary on a caregiver analysis assessing beneficial experiences with trofinetide in patients with Rett syndrome. [WATCH TIME: 4 minutes]

The European evidence generation strategy lead for epilepsy and rare syndromes at UCB Pharma talked about positive results from observational studies assessing the impact of brivaracetam among patients with focal seizures, which was presented at AES 2023. [WATCH TIME: 5 minutes]

Experts conclude their discussion with pearls on the treatment of smouldering multiple sclerosis and prospective advances in medicine.

Experts discuss holistic approaches to care for patients with multiple sclerosis (MS), including lifestyle changes and managing comorbidities.

In an upcoming Peer Exchange program entitled “Dual-Orexin Receptor Antagonists for Treatment of Insomnia” Dr Paul Doghramji will moderate a conversation with physicians about this class of agents for treatment of insomnia and discuss other therapeutic advancements in the field.

In an upcoming Cure Connections program entitled “Barriers to Addressing Sleep Health in Clinical Practice” Dr Paul Doghramji will talk to a patient with insomnia and discuss challenges patients and physicians face when talking about sleep issues and in adequately treating insomnia.

Experts discuss current and emerging treatment options for multiple sclerosis (MS) highlighting the importance of treating early.

Experts explain the biological drivers underlying smouldering multiple sclerosis (MS) and how it might impact treatment modalities.

The senior vice president of medical and clinical affairs for Avadel Pharmaceuticals provided commentary on recently published research supporting once-nightly sodium oxybate (Lumryz) in narcolepsy regardless of the subtype. [WATCH TIME: 5 minutes]

Therapeutic and financial considerations of EVT are explored by a medical expert.

Dr Neelam Gupta highlights differences between recently approved complement inhibitors for treatment of myasthenia gravis.

A neuromuscular disorder specialist, Dr Neelam Goyal shares data with efgartigimod, a neonatal Fc receptor inhibitor, for treatment of myasthenia gravis.

The vice president of the Rare Disease Translational Center at the Jackson Laboratory discussed results from a recently published study reinforcing stathmin-2 as a potential therapeutic strategy for ALS. [WATCH TIME: 4 minutes]

Jason Freeman, MD, MBA, and Abby Rogers, DMSc, PA-C, MPAS, discuss a study presented at ACTRIMS 2023 on high-efficacy disease-modifying therapies for treatment-naïve patients with multiple sclerosis. Sponsored by Novartis.

Jason Freeman, MD, MBA, and Gina Mavrikis Cox, PhD, discuss a presentation from CMSC 2023 on the role of serum biomarkers in multiple sclerosis management. Sponsored by Novartis.

Expert neurologist Dr Lewis discusses the ‘typical’ and CIDP variants, and the new criteria for the variants in the updated guidelines.

Dr Lewis gives a comprehensive overview of CIDP and describes the most common symptoms seen in patients.

Daniel Claassen, MD, MS, reviews emerging treatment options for HD, and shares resources for patients, caregivers, and physicians to navigate diagnosis and management of HD.

An expert neurologist comments on the lack of an approved treatment for HD and examines the evolving treatment landscape, including interest in biomarkers.